Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Ensysce Biosciences Inc. Appoints Dr. D. Lynn Kirkpatrick as President and CEO

Abstract:
Ensysce Biosciences Inc. announced today the appointment of Dr. Lynn Kirkpatrick as President and CEO. Dr. Kirkpatrick has an extensive background in targeted small molecule cancer drug development, and has brought three agents from bench to bedside. Co-founder of ProlX Pharmaceuticals, Dr. Kirkpatrick was CEO from 1999 until its acquisition by Biomira Inc. in 2006. From 2006 through 2008 she was CSO of the merged company, which changed its name to Oncothyreon Inc. in 2007.

Ensysce Biosciences Inc. Appoints Dr. D. Lynn Kirkpatrick as President and CEO

Houston, TX | Posted on January 5th, 2009

"Dr. Kirkpatrick is a tremendous addition to our company," said Bob Gower, Chairman of Ensysce. "Lynn brings a vast array of skills that will help move Ensysce technology rapidly forward building value in the company and moving new technologies to the forefront of cancer treatment."

Ensysce Biosciences, a Houston, TX based nanotechnology company, is focused on the use of carbon nanotubes for therapeutics in the area of cancer treatment. The company has an extensive carbon nanotube-related, worldwide intellectual property portfolio, including IP developed at Rice University by the late Nobel Prize winner Dr Rick Smalley.

Carbon nanotubes provide a means to deliver large active molecular agents without modification through natural barriers within the body and specifically into cancer cells. "This use of carbon nanotubes has been demonstrated in animal studies by our group of collaborators," said Dr. Kirkpatrick. "We have been able to form stable complexes with numerous active entities including short interfering RNA (siRNA) and we believe our current research efforts to tailor their transport and release will ensure a therapeutic benefit as well as eliminating off target effects. Beside delivery, we are exploring other applications of carbon nanotubes to enhance cancer therapies and believe we will enter clinical trials in the next 12 to 18 months."

Ensysce currently has research collaborations with leaders in both the carbon nanotube technology field as well as cancer drug development at M. D. Anderson Cancer Center, Stanford University and Rice University. "siRNA, the most intriguing recent development for cancer treatment has issues with adequate cellular delivery," said Dr. Garth Powis. "Our efforts to use carbon nanotubes to deliver these macromolecules have demonstrated that we can readily transport siRNA into cancer cells with subsequent biological activity. Those are important steps."

Collaborations with Dr. Hongie Dai from Stanford University have also shown that carbon nanotubes can be used to deliver established cancer drugs resulting in tumor regression in animal studies. The complexes provided a significant therapeutic benefit for agents such as taxol and doxorubicin, demonstrating excellent proof of principle of this exciting novel technology.

####

About Ensysce Biosciences Inc.
Ensysce Biosciences a privately held nanotechnology company in Houston, TX founded in 2008, is focused on the use of fullerene carbon nanotubes for therapeutic applications specifically in cancer.

For more information, please click here

Contacts:

Ensysce Biosciences Inc., Houston
Dr. Bob Gower
713-932-6867

or
Dr. Lynn Kirkpatrick
713-864-7512

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Aculon Hires New Business Development Director December 19th, 2014

Iranian Scientists Use Nanotechnology to Increase Power, Energy of Supercapacitors December 18th, 2014

Nanotubes/Buckyballs

A sponge-like molecular cage for purification of fullerenes December 15th, 2014

'Trojan horse' proteins used to target hard-to-reach cancers: Scientists at Brunel University London have found a way of targeting hard-to-reach cancers and degenerative diseases using nanoparticles, but without causing the damaging side effects the treatment normally brings December 11th, 2014

Detecting gases wirelessly and cheaply: New sensor can transmit information on hazardous chemicals or food spoilage to a smartphone December 8th, 2014

Green meets nano: Scientists at TU Darmstadt create multifunctional nanotubes using nontoxic materials December 3rd, 2014

Nanomedicine

Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014

Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014

Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial December 17th, 2014

Unraveling the light of fireflies December 17th, 2014

Announcements

Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014

Instant-start computers possible with new breakthrough December 19th, 2014

Aculon Hires New Business Development Director December 19th, 2014

Iranian Scientists Use Nanotechnology to Increase Power, Energy of Supercapacitors December 18th, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Aculon Hires New Business Development Director December 19th, 2014

Nanomedicine expert joins Rice faculty: Gang Bao combines genetic, nano and imaging techniques to fight disease December 17th, 2014

Nexeon Attracts ex-Nokia Product Executive to its Board of Directors December 15th, 2014

Arrowhead Appoints Patrick O'Brien as General Counsel December 4th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE